Jim Cramer’s daily rapid fire looks at stocks in the news outside the CNBC Investing Club portfolio. Merck : The drugmaker reported a better-than-expected quarter. It raised its full-year sales outlook but was still a little short of estimates. The stock lost nearly 9%. Merck’s acquisition of Acceleron and its pulmonary arterial hypertension treatment three years ago for $11.5 billion is about to pay off. The FDA approved it. Jim Cramer said Tuesday he would take advantage of the dip and buy Merck ahead of the benefit from this drug. Pfizer : Better-than-expected sales and adjusted earnings, as well as a full-year outlook raise, were not enough to keep the stock higher. It fell 2.5%. Cramer was fairly non-committal on the name. “Pfizer is fine. Not great. Not bad.” PayPal : The digital payments company reported a better-than-expected quarter. The new CEO, Alex Chriss, knows what he’s doing, Cramer said. “I would buy the stock.” Howmet Aerospace : The maker of parts for the aerospace and transportation industries delivered a better-than-expected second quarter and the stock soared more than 13%. “The demand for anything aerospace is intense,” Cramer said. “That means this company can make you money.” SoFi Technologies : The financial services company shares were slightly higher after earnings Tuesday but have since fallen. “It can’t get traction,” Cramer said. That’s because investors want growth like a bank and CEO Anthony Noto is trying to make it “more like a software company,” he said.
Jim Cramer: Merck is a buy after the drugmaker’s post-earnings dip — here’s why
